Literature DB >> 9674328

Choosing an antibiotic on the basis of pharmacodynamics.

W A Craig1.   

Abstract

Although standard parameters of antimicrobial activity such as minimal inhibitory concentration (MIC) and minimal bactericidal concentration are useful, they do not provide information about the time course or rate of kill relative to concentration or whether post-antibiotic effects on leukocytes contribute to activity. Antibiotics can be divided into two major groups: those that exhibit concentration-dependent killing and prolonged persistent effects and those that exhibit time-dependent killing and minimal-to-moderate persistent effects. With drugs that fall into the former group, the area under the concentration-time curve (AUC) and peak levels are the major parameters correlating with efficacy. The ratio of peak concentration to MIC is a measure of potency that also indicates the efficacy of the drug. With drugs that exhibit time-dependent killing and minimal-to-moderate persistent effects, time above MIC is the major parameter determining efficacy. Beta-lactam and macrolide antibiotics fall into this second group. Studies in otitis media show that there appears to be a relationship between the time above MIC in serum and in middle ear fluid (MEF) for beta-lactam antibiotics. It is predicted that to achieve at least 80-85% bacteriologic cure in otitis media, serum concentrations should exceed the MIC of pathogens for at least 40% of the dosing interval. For the same cure rate, the peak MEF to MIC ratio should be in the range of 3-6. If the MICs for pathogens are known, it will be possible to predict those for which adequate concentrations can be achieved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674328

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  28 in total

Review 1.  Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.

Authors:  S J Schrag; B Beall; S F Dowell
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.

Authors:  M A Zeitlinger; P Dehghanyar; B X Mayer; B S Schenk; U Neckel; G Heinz; A Georgopoulos; M Müller; C Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 3.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

5.  Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

Authors:  Johan W Mouton; Anne Schmitt-Hoffmann; Stuart Shapiro; Norman Nashed; Nieko C Punt
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

6.  Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Wil H F Goessens; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

7.  Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice.

Authors:  M C Lecaroz; M J Blanco-Prieto; M A Campanero; H Salman; C Gamazo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 8.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 9.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.